Fondaparinux Market Growth & Trends

The global fondaparinux market size is estimated to reach USD 990.9 million by 2030, registering to grow at a CAGR of 6.3% from 2025 to 2030 according to a new report by Grand View Research, Inc. Fondaparinux is majorly used during knee and hip replacement surgeries. Arixtra, manufactured by GSK group of companies is the branded drug of Fondaparinux. The drug witnessed patent expiry in 2002. As the active molecule is highly complex to manufacture, it faced low generic competition until 2011. Generic manufacturer companies, such as Alchemia Ltd. and Apotex, Inc., received the Abbreviated New Drug Application approval in 2011 and instantly started the production of generic drugs.

Fondaparinux is used as an anticoagulant and shows improved survival compared with low-molecular-weight heparin. It is used for the prevention of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and is administered subcutaneously. Moreover, Fondaparinux lowers the risk of ischemic events

Get a preview of the latest developments in the Fondaparinux Market; Download your FREE sample PDF copy today and explore key data and trends

The increasing collaboration between the key players for acquiring the Intellectual Property Rights (IPRs) in order to manufacture the molecule through patented technology is expected to drive growth. For instance, in July 2016 Dr. Reddy’s Laboratories Ltd. entered into an agreement with Alchemia Ltd. to purchase the IPRs of fondaparinux sodium for USD 17.5 million. In September 2014, Mylan N.V. purchased branded and generic versions of fondaparinux sodium from Aspen Global, Inc. for USD 225 million. The deal gave Mylan N.V. access to one of the two generics indicated for the treatment of PE.

Fondaparinux Market Report Highlights

• The generic segment accounted for the largest revenue share of 52.1% in 2024 and is expected to maintain its dominance during the forecast period.
• The Deep Vein Thrombosis (DVT) segment accounted for a leading share of the market in 2024.
• Hospital pharmacies emerged as the leading distribution channel for fondaparinux in 2024
• North America fondaparinux market dominated the global market and accounted for the largest revenue share of 37.6% in 2024

Fondaparinux Market Segmentation

Grand View Research has segmented the global fondaparinux market report based on type, product, distribution channel, and region:

Fondaparinux Type Outlook (Revenue, USD Million, 2018 - 2030)

• Deep Vein Thrombosis
• Pulmonary Embolism

Fondaparinux Product Outlook (Revenue, USD Million, 2018 - 2030)

• Branded
• Generic

Fondaparinux Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Fondaparinux Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• South Korea
• Australia
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Curious about the Fondaparinux Market? Download your FREE sample copy now and get a sneak peek into the latest insights and trends.